BRPI1013422A2 - derivados de oxadiazol - Google Patents

derivados de oxadiazol

Info

Publication number
BRPI1013422A2
BRPI1013422A2 BRPI1013422A BRPI1013422A BRPI1013422A2 BR PI1013422 A2 BRPI1013422 A2 BR PI1013422A2 BR PI1013422 A BRPI1013422 A BR PI1013422A BR PI1013422 A BRPI1013422 A BR PI1013422A BR PI1013422 A2 BRPI1013422 A2 BR PI1013422A2
Authority
BR
Brazil
Prior art keywords
oxadiazole derivatives
oxadiazole
derivatives
Prior art date
Application number
BRPI1013422A
Other languages
English (en)
Inventor
Agnes Bombrun
Anna Quattropani
Cyril Montagne
Stefano Crosignani
Wolfgang Sauer
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of BRPI1013422A2 publication Critical patent/BRPI1013422A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1013422A 2009-04-03 2010-03-29 derivados de oxadiazol BRPI1013422A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157301A EP2241558A1 (en) 2009-04-03 2009-04-03 Oxadiazole derivatives
US16977309P 2009-04-16 2009-04-16
PCT/EP2010/054100 WO2010115751A2 (en) 2009-04-03 2010-03-29 Oxadiazole derivatives

Publications (1)

Publication Number Publication Date
BRPI1013422A2 true BRPI1013422A2 (pt) 2016-04-05

Family

ID=40792794

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1015048A BRPI1015048A2 (pt) 2009-04-03 2010-03-29 derivados de oxadiazol.
BRPI1013422A BRPI1013422A2 (pt) 2009-04-03 2010-03-29 derivados de oxadiazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI1015048A BRPI1015048A2 (pt) 2009-04-03 2010-03-29 derivados de oxadiazol.

Country Status (16)

Country Link
US (2) US8815919B2 (pt)
EP (3) EP2241558A1 (pt)
JP (2) JP5833538B2 (pt)
KR (2) KR20120002606A (pt)
CN (2) CN102803238B (pt)
AR (2) AR076188A1 (pt)
AU (2) AU2010230314B2 (pt)
BR (2) BRPI1015048A2 (pt)
CA (2) CA2755928C (pt)
EA (2) EA201171210A1 (pt)
ES (2) ES2639028T3 (pt)
IL (2) IL215497B (pt)
MX (2) MX2011010451A (pt)
SG (2) SG174448A1 (pt)
WO (2) WO2010112461A1 (pt)
ZA (2) ZA201106854B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
NZ610145A (en) * 2010-10-14 2015-02-27 Daiichi Sankyo Co Ltd Acylbenzene derivative having a hypoglycemic action and/or a β cell- or pancreas-protecting action
HK1200824A1 (en) 2012-01-18 2015-08-14 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
CA2876215A1 (en) 2012-07-02 2014-01-09 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
SI2958913T1 (sl) 2013-02-20 2018-12-31 Lg Chem, Ltd. Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo
CN103450171B (zh) * 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
MX2017000184A (es) * 2014-06-26 2017-09-15 Univ Monash Agentes de interaccion enzimatica.
HK1251965A1 (zh) * 2015-10-30 2019-05-10 Ptc医疗公司 用於治疗癫痫的方法
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用
CN109956912B (zh) * 2017-12-26 2021-10-22 中国医学科学院药物研究所 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途
CN109761827A (zh) * 2019-02-18 2019-05-17 湖南科瑞生物制药股份有限公司 一种n-苄基乙醇胺的制备方法
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN116041277B (zh) * 2023-01-18 2024-11-01 中国药科大学 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用
CN120842164A (zh) * 2024-04-28 2025-10-28 复旦大学 S1pr1特异性激动剂及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003202994B2 (en) * 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
AU2004299456B2 (en) * 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
JP2008545767A (ja) * 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
US20100087491A1 (en) * 2006-09-29 2010-04-08 Rainer Albert Polycyclic compounds
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0625648D0 (en) * 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
JP2010521450A (ja) * 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
EP2014653A1 (en) * 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
EA201070422A1 (ru) * 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives

Also Published As

Publication number Publication date
MX2011010449A (es) 2011-11-18
CA2755918A1 (en) 2010-10-14
JP5833538B2 (ja) 2015-12-16
EP2414342A1 (en) 2012-02-08
AU2010233932B2 (en) 2016-10-13
EA201171211A1 (ru) 2012-05-30
WO2010115751A3 (en) 2010-12-16
SG174448A1 (en) 2011-10-28
AR076188A1 (es) 2011-05-26
EP2414342B1 (en) 2017-05-31
IL215498A (en) 2017-11-30
JP2012522744A (ja) 2012-09-27
US8802704B2 (en) 2014-08-12
CA2755918C (en) 2018-02-20
CN102803238B (zh) 2015-09-30
CN102459206A (zh) 2012-05-16
EP2414341A2 (en) 2012-02-08
US20120022109A1 (en) 2012-01-26
AU2010230314B2 (en) 2016-07-21
KR20110135987A (ko) 2011-12-20
ES2639028T3 (es) 2017-10-25
WO2010112461A1 (en) 2010-10-07
CN102803238A (zh) 2012-11-28
ES2652183T3 (es) 2018-01-31
EP2241558A1 (en) 2010-10-20
IL215498A0 (en) 2011-12-29
IL215497B (en) 2018-12-31
BRPI1015048A2 (pt) 2019-09-24
EP2414341B1 (en) 2017-09-13
KR20120002606A (ko) 2012-01-06
US8815919B2 (en) 2014-08-26
CA2755928C (en) 2017-06-20
EA201171210A1 (ru) 2012-05-30
EA020691B1 (ru) 2015-01-30
MX2011010451A (es) 2011-11-18
JP5833537B2 (ja) 2015-12-16
IL215497A0 (en) 2011-12-29
US20120035226A1 (en) 2012-02-09
AR076187A1 (es) 2011-05-26
WO2010115751A2 (en) 2010-10-14
ZA201106855B (en) 2012-11-28
JP2012522745A (ja) 2012-09-27
CA2755928A1 (en) 2010-10-07
ZA201106854B (en) 2012-11-28
SG174449A1 (en) 2011-10-28
AU2010230314A1 (en) 2011-10-13
AU2010233932A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
BRPI1015048A2 (pt) derivados de oxadiazol.
BRPI0818457A2 (pt) Derivados de oxadiazol
BRPI1013246A2 (pt) derivados de benzofuralina
ECSP12011999A (es) Derivados benzamida sustituidos
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
EP2511268A4 (en) oxazine
DK2443102T3 (da) Herbicidale benzoxazinoner
EP2466205A4 (en) Combustor
DK2397480T3 (da) Diazepindionderivat
BR112012008061A2 (pt) compostos de oxima heterocíclica
BRPI1013844A2 (pt) derivados de piridina-isoxazol
PL2254887T3 (pl) Pochodne oksazolidynonu
BR112012005503A2 (pt) derivados de isoxazolidina
EP2509424A4 (en) NOVEL OXADIAZOLE COMPOUNDS
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BR112012002334A2 (pt) sensor com orifício para transcontactação
BRPI1007495A2 (pt) detonador
DK2387580T3 (da) Deoxyactagardinderivater
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
BRPI1016192A8 (pt) derivados de isoxazol
BRPI1011416A2 (pt) derivados de antraquinova novos
DK2442870T3 (da) Pyrazinooxazepin-derivater.
EP2397799A4 (en) COOLER
DK2421869T3 (da) Rifamycinderivat
BRPI1010702A2 (pt) acendedor com ignição piezelétrica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.